Adhera Therapeutics (ATRX) News Today Add Compare Share Share Headlines Stock AnalysisChartSEC FilingsBuy This Stock ATRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Adhera Therapeutics Inc (ATRX)January 30, 2024 | investing.comATRX Adhera Therapeutics, Inc.August 24, 2023 | seekingalpha.comIntensity Therapeutics upsizes proposed IPO to $15M from $8MMay 21, 2023 | seekingalpha.comAdhera Therapeutics, Inc. (ATRX)February 26, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 25, 2023 | finance.yahoo.comCGTX Cognition Therapeutics, Inc.January 18, 2023 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringDecember 5, 2022 | seekingalpha.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsOctober 9, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistSeptember 19, 2022 | finance.yahoo.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistSeptember 19, 2022 | seekingalpha.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | seekingalpha.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsNovember 8, 2021 | finance.yahoo.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...October 20, 2021 | apnews.comAAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsOctober 20, 2021 | finance.yahoo.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...October 16, 2021 | apnews.comAManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s DiseaseOctober 15, 2021 | finance.yahoo.comAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasOctober 4, 2021 | finance.yahoo.com5 Penny Stocks with Upcoming Growth CatalystsSeptember 15, 2021 | insidermonkey.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...September 13, 2021 | apnews.comAAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsSeptember 13, 2021 | finance.yahoo.comAdhera Therapeutics Appoints Dr. Andrew Reaume to Board of DirectorsSeptember 9, 2021 | finance.yahoo.comAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New ...August 24, 2021 | apnews.comAAdhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug CandidateAugust 24, 2021 | finance.yahoo.comMelior Pharmaceuticals signs multimillion-dollar licensing deal for its experimental Parkinson's disease treatmentAugust 2, 2021 | bizjournals.comShares Spike On an Old Drug Being Used As a New Class of Drugs for Parkinson’s DiseaseJuly 29, 2021 | baystreet.caAdhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug CandidateJuly 29, 2021 | finance.yahoo.com Get Adhera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRX Media Mentions By Week ATRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRX News Sentiment▼0.000.77▲Average Medical News Sentiment ATRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRX Articles This Week▼00▲ATRX Articles Average Week Get the Latest News and Ratings for ATRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adhera Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VINC News OMGAQ News NCNA News HENC News VRPX News TRVN News SYRS News FFNTF News NVS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ATRX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adhera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
